Lilly's obesity pill hits nearly 4000 prescriptions in second week after launch [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
week after its launch earlier this ?month, according to analysts citing IQVIA data. The pill, branded as Foundayo, had 1,390 ?prescriptions in its debut week. Investors are closely watching the rollout as a key test of whether Lilly can gain share from Danish rival Novo Nordisk, which had a first-mover advantage in the oral ?obesity drug market. Novo's Wegovy ?pill, which has been on the market since January, had 18,410 prescriptions in its second week, up ?from 3,071 in its first week. "While we believe comparisons early into launch should be considered immaterial, Foundayo's uptake this week is likely ?to be ?received negatively," said RBC Capital ?Markets analyst Trung Huynh. Shares of ?the drugmaker were trading 1.5% lower before the bell, while U.S.-listed Novo shares were 2% higher. This represents a somewhat slower ramp compared to oral Wegovy, said J.P. Morgan analyst Chris Schott, adding it is not surprising given Wegovy's advantages in time to market ?and brand r
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Eli Lilly slips as obesity scripts said to trail those for Novo's Wegovy [Seeking Alpha]Seeking Alpha
- Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026) [Yahoo! Finance]Yahoo! Finance
- How Dave Ricks keeps Lilly looking beyond its hit weight loss drugs [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk A/S (NVO) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d+)".MarketBeat
- Hims & Hers jumps 7% after expanding partnership with Eli Lilly [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/20/26 - Form 6-K
- 4/20/26 - Form 6-K
- 4/13/26 - Form 6-K
- NVO's page on the SEC website